Characterization of the response of symptomatic benign prostatic hyperplasia (BPH) to terazosin by prostate size

Claus Roehrborn, Peter Boyle, Robert J. Padley, Peggy J. Olson

Research output: Contribution to journalArticle

Abstract

Objective: To assess whether a differential treatment response occurs with the alpha blocker terazosin in the treatment of men with symptomatic benign prostatic hyperplasia (BPH) when stratifying patients by baseline prostate volume. Materials and Methods: Data were combined from three randomized, placebo-controlled, double-blind trials which were three (n=198), six (n=313) and 12 (n=606) months in duration, and used similar enrollment criteria, with a terazosin dose ranging from 2 to 20 mg daily. Results: 1117 men were enrolled with a mean age of 64 ±7.1 (mean ± SE) years, a prostate volume determined by transrectal ultrasonography of 34.0±0.5 ml, a baseline symptom score of 17.3±6.4 AUA units, and a peak flow rate of 9.8±2.7 ml/sec. Two cohorts were formed stratified by baseline prostate volume: 71.3% had a volume of <40 ml with a mean of 25.5±0.2 ml, and 28.7% had volumes of ≥40 ml with a mean of 55.111.1 ml. The two cohorts were virtually identical at baseline regarding age, weight, symptom score and flow rate. Terazosin (n=636) and placebo (n=481) patients were well randomized. The following changes in outcome measures (difference between baseline and final visit) were noted: Terazosin Placebo Symptom Score (AUA Units) < 40ml -6.8±0.3 (-39%)* -3.9±0.4 (-23%) ≥ 40 ml -6.6±0.5 (-38%)* -3.4±0.6 (-18%) Peak Flow Rate (ml/sec) <40ml +2.7±0.2 (+28%)* +1.410.2 (+14%) ≥ 40 ml +2.8±0.4 (+31 %)* +0.9±0.4 (+9%) Conclusions: The terazosin responses are statistically significantly (*p<0.001) different from placebo. While the magnitude of symptom score and flow rate improvement under terazosin is independent of baseline prostate volume, the placebo effect appears to be diminished in men with larger prostates.

Original languageEnglish (US)
Number of pages1
JournalBritish Journal of Urology
Volume80
Issue numberSUPPL. 2
StatePublished - Dec 1 1997

Fingerprint

Terazosin
Prostatic Hyperplasia
Prostate
Placebos
Placebo Effect
Ultrasonography

ASJC Scopus subject areas

  • Urology

Cite this

Characterization of the response of symptomatic benign prostatic hyperplasia (BPH) to terazosin by prostate size. / Roehrborn, Claus; Boyle, Peter; Padley, Robert J.; Olson, Peggy J.

In: British Journal of Urology, Vol. 80, No. SUPPL. 2, 01.12.1997.

Research output: Contribution to journalArticle

@article{b3d8d40eea0347cea2708ec1623ce917,
title = "Characterization of the response of symptomatic benign prostatic hyperplasia (BPH) to terazosin by prostate size",
abstract = "Objective: To assess whether a differential treatment response occurs with the alpha blocker terazosin in the treatment of men with symptomatic benign prostatic hyperplasia (BPH) when stratifying patients by baseline prostate volume. Materials and Methods: Data were combined from three randomized, placebo-controlled, double-blind trials which were three (n=198), six (n=313) and 12 (n=606) months in duration, and used similar enrollment criteria, with a terazosin dose ranging from 2 to 20 mg daily. Results: 1117 men were enrolled with a mean age of 64 ±7.1 (mean ± SE) years, a prostate volume determined by transrectal ultrasonography of 34.0±0.5 ml, a baseline symptom score of 17.3±6.4 AUA units, and a peak flow rate of 9.8±2.7 ml/sec. Two cohorts were formed stratified by baseline prostate volume: 71.3{\%} had a volume of <40 ml with a mean of 25.5±0.2 ml, and 28.7{\%} had volumes of ≥40 ml with a mean of 55.111.1 ml. The two cohorts were virtually identical at baseline regarding age, weight, symptom score and flow rate. Terazosin (n=636) and placebo (n=481) patients were well randomized. The following changes in outcome measures (difference between baseline and final visit) were noted: Terazosin Placebo Symptom Score (AUA Units) < 40ml -6.8±0.3 (-39{\%})* -3.9±0.4 (-23{\%}) ≥ 40 ml -6.6±0.5 (-38{\%})* -3.4±0.6 (-18{\%}) Peak Flow Rate (ml/sec) <40ml +2.7±0.2 (+28{\%})* +1.410.2 (+14{\%}) ≥ 40 ml +2.8±0.4 (+31 {\%})* +0.9±0.4 (+9{\%}) Conclusions: The terazosin responses are statistically significantly (*p<0.001) different from placebo. While the magnitude of symptom score and flow rate improvement under terazosin is independent of baseline prostate volume, the placebo effect appears to be diminished in men with larger prostates.",
author = "Claus Roehrborn and Peter Boyle and Padley, {Robert J.} and Olson, {Peggy J.}",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "80",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Characterization of the response of symptomatic benign prostatic hyperplasia (BPH) to terazosin by prostate size

AU - Roehrborn, Claus

AU - Boyle, Peter

AU - Padley, Robert J.

AU - Olson, Peggy J.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Objective: To assess whether a differential treatment response occurs with the alpha blocker terazosin in the treatment of men with symptomatic benign prostatic hyperplasia (BPH) when stratifying patients by baseline prostate volume. Materials and Methods: Data were combined from three randomized, placebo-controlled, double-blind trials which were three (n=198), six (n=313) and 12 (n=606) months in duration, and used similar enrollment criteria, with a terazosin dose ranging from 2 to 20 mg daily. Results: 1117 men were enrolled with a mean age of 64 ±7.1 (mean ± SE) years, a prostate volume determined by transrectal ultrasonography of 34.0±0.5 ml, a baseline symptom score of 17.3±6.4 AUA units, and a peak flow rate of 9.8±2.7 ml/sec. Two cohorts were formed stratified by baseline prostate volume: 71.3% had a volume of <40 ml with a mean of 25.5±0.2 ml, and 28.7% had volumes of ≥40 ml with a mean of 55.111.1 ml. The two cohorts were virtually identical at baseline regarding age, weight, symptom score and flow rate. Terazosin (n=636) and placebo (n=481) patients were well randomized. The following changes in outcome measures (difference between baseline and final visit) were noted: Terazosin Placebo Symptom Score (AUA Units) < 40ml -6.8±0.3 (-39%)* -3.9±0.4 (-23%) ≥ 40 ml -6.6±0.5 (-38%)* -3.4±0.6 (-18%) Peak Flow Rate (ml/sec) <40ml +2.7±0.2 (+28%)* +1.410.2 (+14%) ≥ 40 ml +2.8±0.4 (+31 %)* +0.9±0.4 (+9%) Conclusions: The terazosin responses are statistically significantly (*p<0.001) different from placebo. While the magnitude of symptom score and flow rate improvement under terazosin is independent of baseline prostate volume, the placebo effect appears to be diminished in men with larger prostates.

AB - Objective: To assess whether a differential treatment response occurs with the alpha blocker terazosin in the treatment of men with symptomatic benign prostatic hyperplasia (BPH) when stratifying patients by baseline prostate volume. Materials and Methods: Data were combined from three randomized, placebo-controlled, double-blind trials which were three (n=198), six (n=313) and 12 (n=606) months in duration, and used similar enrollment criteria, with a terazosin dose ranging from 2 to 20 mg daily. Results: 1117 men were enrolled with a mean age of 64 ±7.1 (mean ± SE) years, a prostate volume determined by transrectal ultrasonography of 34.0±0.5 ml, a baseline symptom score of 17.3±6.4 AUA units, and a peak flow rate of 9.8±2.7 ml/sec. Two cohorts were formed stratified by baseline prostate volume: 71.3% had a volume of <40 ml with a mean of 25.5±0.2 ml, and 28.7% had volumes of ≥40 ml with a mean of 55.111.1 ml. The two cohorts were virtually identical at baseline regarding age, weight, symptom score and flow rate. Terazosin (n=636) and placebo (n=481) patients were well randomized. The following changes in outcome measures (difference between baseline and final visit) were noted: Terazosin Placebo Symptom Score (AUA Units) < 40ml -6.8±0.3 (-39%)* -3.9±0.4 (-23%) ≥ 40 ml -6.6±0.5 (-38%)* -3.4±0.6 (-18%) Peak Flow Rate (ml/sec) <40ml +2.7±0.2 (+28%)* +1.410.2 (+14%) ≥ 40 ml +2.8±0.4 (+31 %)* +0.9±0.4 (+9%) Conclusions: The terazosin responses are statistically significantly (*p<0.001) different from placebo. While the magnitude of symptom score and flow rate improvement under terazosin is independent of baseline prostate volume, the placebo effect appears to be diminished in men with larger prostates.

UR - http://www.scopus.com/inward/record.url?scp=33749280750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749280750&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749280750

VL - 80

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - SUPPL. 2

ER -